The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pirfenidone for Diabetic Nephropathy
Open accessAbstract
Pirfenidone is an oral antifibrotic agent that benefits diabetic nephropathy in animal models, but whether it is effective for human diabetic nephropathy is unknown. We conducted a randomized, double-blind, placebo-controlled study in 77 subjects with diabetic nephropathy who had elevated albuminuria and reduced estimated GFR (eGFR) (20 to 75 ml/min per 1.73 m²). The prespecified primary outcome was a change in eGFR after 1 year of therapy. We randomly assigned 26 subjects to placebo, 26 to pirfenidone at 1200 mg/d, and 25 to pirfenidone at 2400 mg/d. Among the 52 subjects who completed the study, the mean eGFR increased in the pirfenidone 1200-mg/d group (+3.3 ± 8.5 ml/min per 1.73 m²) whereas the mean eGFR decreased in the placebo group (-2.2 ± 4.8 ml/min per 1.73 m²; P = 0.026 versus pirfenidone at 1200 mg/d). The dropout rate was high (11 of 25) in the pirfenidone 2400-mg/d group, and the change in eGFR was not significantly different from placebo (-1.9 ± 6.7 ml/min per 1.73 m²). Of the 77 subjects, 4 initiated hemodialysis in the placebo group, 1 in the pirfenidone 2400-mg/d group, and none in the pirfenidone 1200-mg/d group during the study (P = 0.25). Baseline levels of plasma biomarkers of inflammation and fibrosis significantly correlated with baseline eGFR but did not predict response to therapy. In conclusion, these results suggest that pirfenidone is a promising agent for individuals with overt diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Reversal of Lesions of Diabetic Nephropathy after Pancreas Transplantation
Fioretto, P., Steffes, M. W., Sutherland, D. E. R., Goetz, F. C., & Mauer, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390202 · Cited by 1,135
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Self-citationLarsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Sharma, K., Jin, Y., Guo, J., & Ziyadeh, F. N. (1996) · Diabetes · doi:10.2337/diab.45.4.522 · Cited by 662
Self-citationParker, B. D., Schurgers, L. J., Brandenburg, V. M., Christenson, R. H., Vermeer, C., Ketteler, M., Shlipak, M. G., Whooley, M. A., & Ix, J. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-10-201005180-00004 · Cited by 457
Self-citationMesangial Expansion as a Central Mechanism for Loss of Kidney Function in Diabetic Patients
Steffes, M. W., Østerby, R., Chavers, B., & Mauer, S. M. (1989) · Diabetes · doi:10.2337/diab.38.9.1077 · Cited by 440
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · PubMed · Cited by 358
Eijkelkamp, W. B. A., Zhang, Z., Remuzzi, G., Parving, H.-H., Cooper, M. E., Keane, W. F., Shahinfar, S., Gleim, G. W., Weir, M. R., Brenner, B. M., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050445 · Cited by 302
Increased Renal Production of Transforming Growth Factor-β1 in Patients with Type II Diabetes
Sharma, K., Ziyadeh, F. N., Alzahabi, B., McGowan, T. A., Kapoor, S., Kurnik, B. R. C., Kurnik, P. B., & Weisberg, L. S. (1997) · Diabetes · doi:10.2337/diab.46.5.854 · Cited by 274
Self-citationRenal interstitial expansion in insulin-dependent diabetes mellitus
Lane, P. H., Steffes, M. W., Fioretto, P., & Mauer, S. M. (1993) · Kidney International · doi:10.1038/ki.1993.95 · Cited by 232
Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis
Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., & Kopp, J. B. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01050207 · Cited by 222
Self-citationEffect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome
Gahl, W. A., Brantly, M., Troendle, J., Avila, N. A., Padua, A., Montalvo, C., Cardona, H., Anton Calis, K., & Gochuico, B. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00044-6 · Cited by 203
Efficiency Study of Estimators for a Treatment Effect in a Pretest–Posttest Trial
Yang, L., & Tsiatis, A. A. (2001) · The American Statistician · doi:10.1198/000313001753272466 · Cited by 184
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35110-9 · Cited by 181
Pirfenidone Is Renoprotective in Diabetic Kidney Disease
RamachandraRao, S. P., Zhu, Y., Ravasi, T., McGowan, T. A., Toh, I., Dunn, S. R., Okada, S., Shaw, M. A., & Sharma, K. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008090931 · Cited by 167
Self-citationSharma, K., Eltayeb, B. O., McGowan, T. A., Dunn, S. R., Alzahabi, B., Rohde, R., Ziyadeh, F. N., & Lewis, E. J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70037-5 · Cited by 161
Self-citationOku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01757-0 · Cited by 159
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1
Ma, L., Nakamura, S., Whitsitt, J. S., Marcantoni, C., Davidson, J. M., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00426.x · Cited by 144
Fioretto, P., Steffes, M. W., Sutherland, D. E. R., & Mauer, M. S. (1995) · Kidney International · doi:10.1038/ki.1995.493 · Cited by 142
Testing for Random Dropouts in Repeated Measurement Data
Ridout, M. S., & Diggle, P. J. (1991) · Biometrics · doi:10.2307/2532413 · Cited by 141
Niewczas, M. A., Ficociello, L., Johnson, A. C., Walker, W., Rosolowsky, E. T., Roshan, B., Warram, J. H., & Królewski, A. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03010608 · Cited by 139
Shihab, F. S., Bennett, W. M., Yi, H. L., & Andoh, T. F. (2002) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2002.020201.x · Cited by 123
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels
Agarwal, R., Siva, S., Dunn, S., & Sharma, K. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.31392 · Cited by 109
Self-citationGrattendick, K. J., Nakashima, J., Feng, L., Giri, S. N., & Margolin, S. B. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.01.013 · Cited by 107
The Death Ligand TRAIL in Diabetic Nephropathy
Lorz, C., Benito‐Martín, A., Boucherot, A., Ucero, A. C., Rastaldi, M. P., Henger, A., Armelloni, S., Accent]a, B. S. A., Berthier, C. C., Kretzler, M., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050581 · Cited by 106
Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats
Tada, S., Nakamuta, M., Enjoji, M., Sugimoto, R., Iwamoto, H., Kato, M., Nakashima, Y., & Nawata, H. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03481.x · Cited by 81
Cellular Basis of Diabetic Nephropathy
Huang, C., Kim, Y., Caramori, M. L., Fish, A. J., Rich, S. S., Miller, M. E., Russell, G. B., & Mauer, M. S. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3577 · Cited by 80
Marsell, R., Grundberg, E., Krajisnik, T., Mallmin, H., Karlsson, M. K., Mellström, D., ORWOLL, E. S., Ohlsson, C., Jonsson, K. B., Ljunggren, Ö., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0534 · Cited by 68
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats
Du, X., Schelegle, E. S., Mohr, F. C., Margolin, S. B., Giri, S. N., & Al-Bayati, M. A. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0703-z · Cited by 62
Role of angiotensin II in glomerular injury
Ma, L., & Fogo, A. B. (2001) · Seminars in Nephrology · doi:10.1053/snep.2001.26793 · Cited by 51
Stimulation of Urinary TGF-β and Isoprostanes in Response to Hyperglycemia in Humans
McGowan, T., Dunn, S., Falkner, B. E., & Sharma, K. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00990905 · Cited by 37
Self-citationOpen-label study of pirfenidone in patients with progressive forms of multiple sclerosis
Bowen, J. D., Maravilla, K. R., & Margolin, S. B. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms907oa · Cited by 27
Trials and Tribulations of New Agents, Novel Biomarkers, and Retarding Renal Progression
Levin, A., & Beaulieu, M. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040402 · Cited by 8
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Kidney fibrosis: from mechanisms to therapeutic medicines
Huang, R., Fu, P., & Ma, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01379-7 · Cited by 781
TGF-β/Smad signaling in renal fibrosis
Meng, X.-M., Tang, P. M.-K., Li, J., & Lan, H. Y. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00082 · Cited by 666
Metadata
- Authors
- Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., Donohue, M., RamachandraRao, S., Xu, R., Fervenza, F. C., & Kopp, J. B.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2011-06
- Volume
- 22
- Issue
- 6
- Pages
- 1144-1151
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2171324990
- Cited by
- 319
- References
- 40
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.